<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552044</url>
  </required_header>
  <id_info>
    <org_study_id>C11-21</org_study_id>
    <secondary_id>2011-003046-40</secondary_id>
    <nct_id>NCT01552044</nct_id>
  </id_info>
  <brief_title>Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis</brief_title>
  <official_title>Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effect of spironolactone on 16 patients
      presenting with chronic non-resolutive central serous chorioretinitis (CSCR) and to evaluate
      whether spironolactone can resolve sub retinal fluid in these patients.

      CSCR is a major cause of visual loss in the young population. It is characterized by sub
      retinal fluid under the retina and retinal pigment epithelial detachments. The exact causes
      of the disease remain unknown but a choroidopathy has been suggested. Moreover,
      corticotherapy and stress are known risk factors of CSCR.

      Our preclinical studies have demonstrated that the mineralocorticoid pathway could be
      involved in the control of choroidal blood flow.

      The investigators propose to evaluate the mineralocorticoid receptors antagonist
      spironolactone in the treatment of CSCR.

      Criteria of efficacy Endpoint: reduction of subretinal fluid ≥ 40 microns Secondary endpoint:
      visual acuity gain ≥ 15 EDTRS letters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective placebo controlled cross over study including 16 patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Central macular thickness</measure>
    <time_frame>1 and 3 months</time_frame>
    <description>Sub retinal fluid decrease &gt; or = 40 microns</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Central Serous Chorioretinitis</condition>
  <arm_group>
    <arm_group_label>spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spironolactone 25mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25mg tablet once a day for 1 month</description>
    <arm_group_label>spironolactone</arm_group_label>
    <other_name>aldactone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one tablet once a day for 1 month</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient between 18 and 60 years

          -  CSCR affecting the macula and non-resolutive for at least 3 months

          -  Patients having given and signed informed consent

          -  Vital prognosis non engaged for the next 6 months.

        Exclusion Criteria:

          -  Other ocular pathology

          -  Neovascularization,

          -  Diabetes

          -  Uveitis

          -  Ocular surgery in the last 3 months

          -  Allergy to fluorescein or indocyanine green

          -  Pregnancy or no contraception

          -  Renal or liver insufficiency

          -  Kaliemia ≥ 5.5 mmol/l Criteria of efficacy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hotel-Dieu of Paris</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retina</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorioretinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

